Christopher Haqq
Patrimonio netto: 89 547 $ in data 31/07/2026
Patrimonio netto: 89 547 $ in data 31/07/2026
Christopher M.
Haqq currently works at Elicio Therapeutics, Inc., as Chief Medical Officer & Executive Vice President from 2019.
Dr. Haqq also formerly worked at Consonance-HFW Acquisition Corp., as Independent Director from 2020 to 2021, Amgen, Inc., as Manager-Early Development Oncology Group, Cougar Biotechnology, Inc., as Vice President-Clinical Research & Development from 2007 to 2009, The University of California, San Francisco, as Assistant Professor, Janssen Oncology, Inc., as Vice President-Clinical Research & Development from 2007 to 2011, Atara Biotherapeutics, Inc., as Chief Scientific Officer, Executive VP-R&D from 2012 to 2019, and Elicio Therapeutics, Inc. (United States), as Chief Medical Officer & Executive Vice President from 2019 to 2023.
Dr. Haqq received his undergraduate degree from Stanford University and doctorate degree from Harvard Medical School.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 16/07/2026 | 31.981 ( 0,14% ) | 89 547 $ | 31/07/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| ELICIO THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/10/2019 |
| Società | Posizione | Fine |
|---|---|---|
Elicio Therapeutics, Inc. (United States)
Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases | Direttore Tecnico/Scientifico/R&S | 01/06/2023 |
| SURROZEN, INC. | Direttore/Membro del Consiglio | 01/04/2021 |
| ATARA BIOTHERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 25/10/2019 |
Janssen Oncology, Inc.
Janssen Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer | Direttore Tecnico/Scientifico/R&S | 01/09/2011 |
Cougar Biotechnology, Inc. /Old/
Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer | Direttore Tecnico/Scientifico/R&S | 13/07/2009 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 10 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Cougar Biotechnology, Inc. /Old/
Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer | Health Technology |
Elicio Therapeutics, Inc. (United States)
Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases | Health Technology |
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Janssen Oncology, Inc.
Janssen Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer | Health Technology |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases | Health Technology |
Consonance-HFW Acquisition Corp.
Consonance-HFW Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. BiotechnologyHealth Technology Develops cancer immunotherapies | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale